Baird Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
Baird analyst Joel Beatty maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $33 to $36.
Baird analyst Joel Beatty maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $33 to $36.